This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Dec;4(6):791.

doi: 10.2217/bmm.10.99.

Backtracking on CYP2C19 genotyping in clopidogrel therapy?

Jason Park¹

Affiliations

Affiliation

¹ Department of Pathology, University of Texas Southwestern Medical Center and Children's Medical Center, 1935 Medical District Drive, Dallas, TX 75235, USA. jaspar@childrens.com

PMID: 21133697
DOI: 10.2217/bmm.10.99

Comment

Backtracking on CYP2C19 genotyping in clopidogrel therapy?

Jason Park. Biomark Med. 2010 Dec.

. 2010 Dec;4(6):791.

doi: 10.2217/bmm.10.99.

Author

Jason Park¹

Affiliation

¹ Department of Pathology, University of Texas Southwestern Medical Center and Children's Medical Center, 1935 Medical District Drive, Dallas, TX 75235, USA. jaspar@childrens.com

PMID: 21133697
DOI: 10.2217/bmm.10.99

No abstract available

PubMed Disclaimer

Comment on

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Paré G, et al. N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29. N Engl J Med. 2010. PMID: 20979470 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.